Investigating how to improve the clearance of harmful proteins in Alzheimer's disease
Official title: Mechanisms and therapeutic potential of the autophagy-lysosome pathway in Alzheimer’s disease
Funded at Sloan-Kettering Inst Can Research · NIH-11062938 · Data updated 2026-11-12
This study is looking at how a protein called TFEB helps clear out harmful substances in the brain related to Alzheimer's disease, and it hopes to find new ways to improve treatments for patients by figuring out how to boost this protein's activity.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Sloan-Kettering Inst Can Research NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project start | January 1, 2025 |
| Project end | December 31, 2029 |
| Funding year | 2025 |
| Award (this year) | $871,093 |
| NIH project number | 1R01AG087529-01A1 |
| Project ID | NIH-11062938 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals aged 65 and older who are experiencing symptoms of Alzheimer's disease or are at risk for developing it.
✕Less likely to help
Patients under the age of 65 or those without Alzheimer's disease may not receive direct benefits from this research.
What this research studies
This research focuses on understanding the mechanisms that regulate a key protein, TFEB, which plays a crucial role in the autophagy-lysosomal pathway involved in Alzheimer's disease. By studying how certain proteins influence TFEB and the clearance of tau aggregates, the research aims to identify potential therapeutic targets that could help mitigate the progression of Alzheimer's. The approach includes both genetic and pharmacological methods to explore how inhibiting specific proteins can enhance the body's ability to clear harmful substances associated with Alzheimer's. Patients may benefit from new treatment strategies that arise from these findings.
Why it matters
Potential benefit: If successful, this research could lead to innovative treatments that improve the clearance of toxic proteins in Alzheimer's disease, potentially slowing its progression.
How similar studies have gone: Previous research has shown promise in targeting similar pathways for Alzheimer's treatment, indicating that this approach could be a viable avenue for further exploration.
Where this research is happening
-
Sloan-Kettering Inst Can Research
New York, United States Active
Researchers
- Principal investigator: Li, Yueming — Sloan-Kettering Inst Can Research
- Study coordinator: Li, Yueming
Related research
Other NIH-funded projects on the same topics.
-
Understanding how brain activity changes may drive Alzheimer’s disease progression in a mouse model
Researchers are testing how changes in brain signals and protein cleanup processes affect the development of Alzheimer’s disease in mice.
-
Thiamine-boosting therapy for Alzheimer’s: understanding how benfotiamine may reduce harmful AGE in DP patients
A medication-based approach using high-dose vitamin B1 (benfotiamine) is studied to help people with Alzheimer's by reducing harmful sugar-related molecules.
-
Non-invasive tears biomarker for early Alzheimer's in LMICs
A low-cost, tear-based biomarker approach aims to detect early Alzheimer’s disease in older adults in Peru and similar settings.
-
Turning APOE4 into protective APOE2 or APOE3Christchurch to help with Alzheimer’s
A patient-facing explanation of a treatment idea that aims to change a genetic risk factor for Alzheimer's disease in the brain.
-
Telomerase in Alzheimer’s Disease: how aging biology could influence memory and brain health
Researchers are exploring a new brain-aging mechanism linked to telomerase, with potential to slow or modify Alzheimer’s disease in people and improve cognitive function.
-
Biomarkers of Alzheimer’s Disease: Sensory, Motor, and Cognitive Clues
Researchers are testing simple sensory and movement tasks to find early signs of Alzheimer’s disease so they can diagnose and treat people sooner.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.